Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 29 September 2015 | By Zachary Brennan
The US Food and Drug Administration (FDA) has added Canada's Cosmetic Manufacturers Inc. (CMI) to a list of companies that have been banned from shipping products to the US.
CMI manufactures cosmeceuticals, nutraceuticals and pharmaceuticals, including a digestive enzyme therapy, according to its website. The company says it has a Drug Establishment License and owns the rights to many Drug Identification Number products under the CMI name.
The updated FDA import alert list did not go into detail about the violations that caused CMI to be added to it, though it did cite current good manufacturing practice (cGMP) issues.
In an FDA warning letter to the company from 2013, agency inspectors at CMI's Concord, Ontario manufacturing site said they identified significant cGMP violations. Among those, the company failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined and released for use by the quality control unit.
CMI also failed to establish and follow written procedures for the preparation of master production and control records, which can assure batch uniformity. The possibility of cross-contamination was another issue FDA cited as a reason for the letter.
In addition, CMI failed to register with the FDA in 2011 and 2012 as a firm that manufactures and imports drugs to the US.
The company could not be reached for comment by press time as the phone number listed on its web site is no longer in service.
Import Alert List
Tags: Cosmetic Manufacturers Inc., Canada pharmaceuticals, FDA import alerts, import alert list
Regulatory Focus newsletters
All the biggest regulatory news and happenings.